Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer - PubMed

3 hours ago

Cyclin-E1 protein overexpression is linked to poor prognosis in high-grade serous ovarian cancer (HGSOC) and may serve as a predictive marker for targeted therapies.
59% of HGSOC tumors overexpressed Cyclin-E1, with over half lacking evidence of CCNE1 gene amplification, indicating overexpression often occurs without amplification.
The prevalence of CCNE1 amplification varies, being higher in interventional studies, and patients with Cyclin-E1 positive tumors have worse outcomes post-adjuvant therapy.
Platinum-based chemotherapy increases Cyclin-E1 expression, and these patients are less likely to benefit from PARP inhibitors or mirvetuximab soravtansine, highlighting a need for novel therapies.
The study, from 2026, involves conflicts of interest, with several authors affiliated with Zentalis Pharmaceuticals and other pharmaceutical companies.

Hasty Briefsbeta